Datapharm joins the Gravitate-Health project

Datapharm is pleased to be one of the partners of Gravitate-Health, a new research consortium funded by Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission that aims to improve access and understanding of health information, for safe use of medicines, risk minimization and improved quality of life.

OECD estimates that around 200,000 premature deaths annually in Europe relate to poor medication adherence, which may cost as much as €125 billion each year in avoidable hospitalization, emergency care and adult outpatient visits.

We are joining forces with other 40 leading partners from public and private sectors in 15 countries to develop innovative patient-focused healthcare information tools that will offer citizens timely access to trustworthy, relevant information about medicines. The project is led by Pfizer and coordinated by the University of Oslo.

Nat Knight, Director of Datapharm, said "We are very excited to be supporting the Gravitate Health project. At Datapharm we devote ourselves to improving the accessibility, effectiveness and excellence of healthcare product information and this is clearly aligned to the Consortium desire to empower patients with digital information tools to help them through the patient journey. It is a pleasure to be working with so many pharmaceutical companies as well as private and public sector institutions".

Arif Govani, Chief Digital Officer, added "We have been working hard on making our product information more accessible and available in formats which enable better health outcomes. We are looking forward to working with pharma and standards organisations like HL7 to further enhance our Medicines Data as a Service (DaaS) product".

For more information about the Gravitate Health project, visit the official website: www.gravitatehealth.eu